Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications. After buying Dren Bio’s B cell depletion ...

Dren Bio, a privately held, clinical-stage biotechnology company developing therapeutics for cancer, autoimmune, and other serious diseases, announced today that it received the 2025 Prix Galien USA ...

"I hope when a producer loads this piano sound, they’ll feel connected to the music that inspired it," Legend said. By Ethan Millman Music Editor John Legend is bringing the iconic piano sound from ...

In 1999, the first human chromosome was sequenced in full thanks to the Human Genome Project. It was a climactic accomplishment for genetic engineering, but it could’ve easily been seen as a Pandora’s ...

Music creation platform Splice has acquired Spitfire Audio, the UK-based developer of high-end virtual instrument libraries. The acquisition marks Splice’s entry into the fast-growing plugin space, ...

Music creation platform Splice has acquired Spitfire Audio, the British sample library and virtual instrument developer, for around $50 million, according to reports in The Financial Times. A press ...

The head of the sample platform thinks creatives “deserve better” than AI tools that do all the work for them. The head of the sample platform thinks creatives “deserve better” than AI tools that do ...

March 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in biobucks ...